14-3-3beta Is a p90 Ribosomal S6 Kinase (RSK) Isoform 1-binding Protein That Negatively Regulates RSK Kinase Activity*

Megan E. Cavet, Stephanie LehouxDagger, and Bradford C. Berk§

From the Center for Cardiovascular Research and Department of Medicine, University of Rochester, Rochester, New York 14642

Received for publication, August 19, 2002, and in revised form, March 3, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

p90 ribosomal S6 kinase 1 (RSK1) is a serine/threonine kinase that is activated by extracellular signal-related kinases 1/2 and phosphoinositide-dependent protein kinase 1 upon mitogen stimulation. Under basal conditions, RSK1 is located in the cytosol and upon stimulation, RSK1 translocates to the plasma membrane where it is fully activated. The ability of RSK1 to bind the adapter protein 14-3-3beta was investigated because RSK1 contains several putative 14-3-3-binding motifs. We demonstrate that RSK1 specifically and directly binds 14-3-3beta . This interaction was dependent on phosphorylation of serine 154 within the motif RLSKEV of RSK1. Binding of RSK1 to 14-3-3beta was maximal under basal conditions and decreased significantly upon mitogen stimulation. After 5 min of serum stimulation, a portion of 14-3-3beta and RSK1 translocated to the membrane fraction, and immunofluorescence studies demonstrated colocalization of RSK1 and 14-3-3beta at the plasma membrane in vivo. Incubation of recombinant RSK1 with 14-3-3beta decreased RSK1 kinase activity by ~50%. Mutation of RSK1 serine 154 increased both basal and serum-stimulated RSK activity. In addition, the epidermal growth factor response of RSK1S154A was enhanced compared with wild type RSK. The amount of RSK1S154A was significantly increased in the membrane fraction under basal conditions. Increased phosphorylation of two sites essential for RSK1 kinase activity (Ser380 and Ser363) in RSK1S154A compared with RSK1 wild type, demonstrated that 14-3-3 interferes with RSK1 phosphorylation. These data suggest that 14-3-3beta binding negatively regulates RSK1 activity to maintain signal specificity and that association/dissociation of the 14-3-3beta -RSK1 complex is likely to be important for mitogen-mediated RSK1 activation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The p90 ribosomal S6 kinase (RSK)1 family members have a role in mitogen-activated cell growth and proliferation, differentiation, and cell survival. RSK is a serine/threonine kinase that is a substrate of ERK1/2 and lies downstream of the Raf/MEK/ERK protein cascade (1). Recent studies have provided insight into mechanisms responsible for activation of RSK1. RSK1 has two distinct domains, both of which are catalytically functional. Phosphorylation of RSK1 by ERK on the carboxyl-terminal catalytic loop activates the RSK1 carboxyl-terminal kinase domain. This induces a conformational change abrogating the negative effect of this domain, allowing activation of the amino-terminal kinase domain by PDK1 (2). Cellular localization is thought to be important in the regulation of RSK activity. Upon mitogen stimulation RSK undergoes a rapid and transient localization to the plasma membrane, which requires ERK docking and phosphorylation. At the plasma membrane PDK1 inputs as well as ERK- and PDK1-independent events lead to full activation of RSK (3). RSK can then phosphorylate its substrates, which include the Na+/H+ exchanger NHE1 isoform at the plasma membrane, nuclear transcription factors, and transcriptional coactivator proteins (1, 4).

14-3-3 proteins are a family of 30-kDa acidic proteins that interact with a wide variety of cellular proteins including protein kinases, receptor proteins, enzymes, structural and cytoskeletal proteins, and small G-proteins (5-8). The predominant 14-3-3-binding motif involves a phosphoserine, but interaction can involve other varied motifs and may not require phosphorylation (9-11). Because 14-3-3 proteins exist as dimers, they can simultaneously bind multiple phosphorylation sites on the same protein (12, 13) or function as scaffolds to form protein-protein interactions (5-8, 14). Other roles of 14-3-3 proteins include regulation of interacting proteins activity, subcellular localization, and/or stability. For example, 14-3-3 proteins are known to act as a scaffold for several proteins in the mitogen-activated protein kinase cascades, including MEKK1, 2, and 3 (15), and to regulate the kinase activity of Raf (16).

Work in our laboratory has shown that NHE1 is activated by mitogens through phosphorylation of serine 703 by RSK (4). Subsequently, 14-3-3beta binds to this site and prevents dephosphorylation of serine 703 (17). In the present study we investigated whether RSK1 was also a binding partner for 14-3-3beta because it contains a number of putative 14-3-3 interaction motifs. We found that 14-3-3beta specifically interacts with RSK1 in a phosphorylation-dependent manner, and the site of interaction was identified as serine 154. RSK-14-3-3beta binding is maximal under quiescent conditions and upon mitogen stimulation; both RSK and 14-3-3beta translocate to the plasma membrane where they presumably dissociate because binding to 14-3-3beta is decreased. Furthermore, 14-3-3beta binding is inhibitory to RSK activity, and RSK1S154A, which does not interact with 14-3-3, has increased activity both basally and upon mitogen stimulation. This study suggests an important role for 14-3-3beta in the negative regulation of RSK kinase activity.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

DNA Constructs and Mutagenesis-- RSK1 and 14-3-3beta point mutations were created using the QuikChange site-directed mutagenesis kit (Stratagene) following the manufacturer's protocol. GST-14-3-3beta was a gift from A. J. Muslin (Washington University School of Medicine). 14-3-3beta constructs were subcloned into pcDNA3.1Xpress/His vector (Invitrogen), and rat RSK1 was subcloned into pCMV-FLAG (Stratagene) or pcDNA3.1/Myc-His (Invitrogen). All of the constructs and mutants were verified by DNA sequencing.

In Vitro Translation of Full-length RSK1-- Full-length rat p90RSK1 under control of the T7 promoter in pcDNA3.1/Myc-His was transcribed and translated in vitro using the TNT T7-coupled reticulocyte lysate system (Promega). The nascent protein was labeled using Transcend biotin-lysyl-tRNA (Promega). Briefly, 40 µl of TNT Quick Master Mix, 1 µl of methionine (1 mM), 1 µg of template DNA, and 1 µl of biotin-lysyl-tRNA were mixed in a final volume of 50 µl, incubated for 90 min at 30 °C, and immediately used for the binding assays.

Cell Culture-- PS127A cells (Chinese hamster lung fibroblasts that overexpress NHE1) were a gift from Dr. J. Pouyssegur (University of Nice, Nice, France). PS127A, NIH3T3, Cos7, and HEK293 cells were grown in Dulbecco's modified Eagle's medium supplemented with 25 mM NaHCO3, 10 mM HEPES, pH 7.4, 50 IU/ml penicillin, 50 µg/ml streptomycin, 10% fetal bovine serum (FBS) in a 5% CO2, 95% O2 incubator at 37 °C. The cells were serum-starved (0% FBS) overnight prior to the experiments.

Preparation of Cell Lysates-- The cell monolayers were rinsed with ice-cold phosphate-buffered saline (150 mM NaCl, 20 mM Na2PO4, pH 7.4) and then scraped in 1 ml of phosphate-buffered saline. After a brief centrifugation, the cells were solubilized in 1 ml of cell lysis buffer (10 mM HEPES, pH 7.4, 50 mM sodium pyrophosphate, 50 mM NaF, 50 mM NaCl, 5 mM EDTA, 5 mM EGTA, 1 mM Na3VO4, 0.5% Triton X-100 plus 1:1000 protease inhibitor mixture (Sigma)). The cells were sonicated for 20 s (in the case of pull-down studies) or needle-homogenized (in the case of coimmunoprecipitations), agitated on a rotating rocker at 4 °C for 30 min, and centrifuged at 12,000 × g for 30 min to remove insoluble cellular debris. For some pull-down experiments, phosphatase treatment of cell lysates was performed by lysing cells in CIAP buffer (20 mM Tris, pH 8, 150 mM NaCl, 1 mM MgCl2, 1 mM dithiothreitol, 0.5% Triton X-100, plus 1:1000 protease inhibitor mixture). The lysates were treated with or without 200 units of calf intestinal alkaline phosphatase (Promega) at 37 °C for 1 h. Where indicated the inhibitors Na3VO4 (1 mM) and NaF (50 mM) were added.

Immunoprecipitations and Pull-downs-- For coimmunoprecipitation studies, HEK293 cells were cotransfected with FLAG-tagged RSK1 and Xpress-tagged 14-3-3beta . Immunoprecipitations were carried out by preclearing cell lysates with protein A/G-agarose (Santa Cruz) for 1 h followed by incubation with anti-Xpress antibody for 3 h and with protein A/G-agarose for a further 1 h or M2 anti-FLAG-agarose beads for 4 h. Pull-downs were performed by incubating 10 µg of GST-14-3-3beta or GST-14-3-3beta K49Q (produced as described previously (17)) bound to glutathione-Sepharose overnight at 4 °C.

Immunoprecipitates and pull-downs were then washed four times with 1 ml of cell lysis buffer before the addition of Laemmli sample buffer. After heating at 95 °C for 3 min, the proteins were resolved on SDS-PAGE and transferred to nitrocellulose membranes for Western analysis. Immunoblotting was performed with anti-Xpress antibody (Invitrogen), M2 anti-FLAG antibody (Sigma), anti-RSK1 antibody (Santa Cruz), anti-14-3-3beta antibody (Santa Cruz), or anti-NHE1 antibody (Chemicon), anti-phospho-RSK1 (Ser363) (Upstate Biotechnology), and anti-phospho-RSK (Ser380) (which was a gift from Dr. C. Chrestensen, University of Virginia). Immunoreactive bands were detected with horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences) and enhanced chemiluminescence.

Preparation of Membrane Fractions-- The cell monolayers were rinsed and scraped in 1 ml of ice-cold phosphate-buffered saline. After a brief centrifugation the cells were resuspended in 750 µl of membrane fractionation buffer (25 mM Tris-HCl, pH 7.4, 5 mM EGTA, 5 mM EDTA, 100 mM NaF, 5 mM dithiothreitol, and 1:1000 protease inhibitor mixture). The lysates were prepared by needle homogenization and nuclei, and unbroken cells were pelleted at 850 × g for 10 min. Equal amounts of protein in postnuclear supernatants were centrifuged at 100,000 × g for 1 h to obtain soluble fractions and total membrane pellets. The soluble fraction was removed, and the membrane pellets were solubilized in 250 µl of buffer containing 1% Triton X-100, sonicated, and rocked for 1 h at 4 °C and analyzed by SDS-PAGE as described above.

RSK1 Kinase Assays-- Twenty milliunits of recombinant RSK1 (Upstate Biotechnology Inc.) was incubated in 30 µl of kinase buffer (30 mM HEPES, pH 7.5, 100 mM NaCl, 10 mM MgCl2, 10 mM MnCl2, and 0.2 mg/ml bovine serum albumin) overnight with 10 µg of GST-14-3-3beta or GST-14-3-3beta K49A. To initiate the kinase reaction, 10 µg of S6 peptide, 7.5 µM ATP, and 5 µCi of [gamma -32P]ATP (Amersham Biosciences) were added, and the reaction was incubated for 10 min at 30 °C. The reaction was terminated by spotting 25 µl of the reaction onto P81 phosphocellulose filter paper. The filters were washed five times in 0.75% phosphoric acid and one time in acetone, and radioactive incorporation was determined by Cerenkov counting.

CREB Reporter Gene Assays-- HEK293 cells were plated at 2 × 105 cells/well in 24-well plates 24 h prior to transfection. The cells were transfected with different expression plasmids together with the activator plasmid for CREB (pFA2-CREB) and the reporter gene for luciferase (pFR-Luc) (Stratagene). A plasmid expressing the enzyme Renilla luciferase was used as an internal control (pRL-TK; Promega). After 24 h, the cells were serum-starved for 24 h and then stimulated as indicated. Firefly and Renilla luciferase activities were measured using a Dual Luciferase Reporter System (Promega) with a Wallac 1420 luminometer. The data are expressed as firefly luciferase normalized by Renilla luciferase activity.

Immunocytochemistry and Confocal Microscopy-- Cos7 cells seeded on glass coverslips were transfected with pCMV-FLAG-RSK1 using LipofectAMINE 2000. After 24 h the cells were serum-starved for a further 12 h and treated with 20% FBS. The cells were fixed in 3% paraformaldehyde, permeabilized with 0.2% Triton X-100, and blocked in phosphate-buffered saline with 5% FBS, 0.2% bovine serum albumin. The cells were stained with anti-FLAG antibody to visualize RSK1 and anti-14-3-3beta antibody and then incubated in secondary antibodies (Vector). The images were acquired using an Olympus IX70 Fluoview confocal microscope.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

RSK1 Binds 14-3-3beta in Vitro and in Vivo-- Previously our laboratory has demonstrated a direct interaction between the Na+/H+ exchanger isoform NHE1 and 14-3-3beta at serine 703, the site of NHE1 phosphorylation by RSK (17). Because phosphorylation by RSK on serine 703 is required for binding of the scaffolding protein 14-3-3 and RSK1 contains several putative 14-3-3-binding sites similar to the consensus 14-3-3-binding motif RSXpSXP, we investigated whether 14-3-3beta could interact with RSK1. Indeed, we found that RSK1 from extracts of PS127 fibroblasts was able to bind 14-3-3beta in vitro (Fig. 1A). Previously, lysine 49 has been shown to be essential for interaction with 14-3-3-binding partners Bcr, Raf, and Cbl via a phosphoserine type interaction (18, 19). Mutation of lysine 49 (K49A) in 14-3-3beta abolished NHE1 interaction with 14-3-3 (17). This mutation also abolished binding of RSK1 to 14-3-3beta . In addition, GST alone was unable to bind to RSK1 (Fig. 1A).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 1.   14-3-3beta binds to RSK1 in vitro and in vivo. A, PS127 cells were lysed, and a pull-down assay was performed with GST-14-3-3, GST-14-3-3 K49Q, or GST beads. B, biotin-labeled RSK1 was synthesized by in vitro translation and incubated with GST-14-3-3beta or GST-14-3-3beta K49Q. Proteins bound to beads were subjected to SDS-PAGE and blotted with horseradish peroxidase-streptavidin. C, HEK293 cells were transfected with FLAG-RSK1 and Xpress-14-3-3beta . Cells transfected with empty vector were used as a control. The cell lysates (lanes 1 and 2) were immunoprecipitated (IP) with anti-Xpress antibody (lanes 3 and 4) or M2 anti-FLAG-agarose beads (lanes 5 and 6) and immunoblotted for FLAG-RSK1 and Xpress-14-3-3beta .

To determine whether the interaction between 14-3-3beta and RSK1 was direct, full-length RSK was synthesized by in vitro translation, and its ability to bind to GST-14-3-3beta was determined. In vitro translated RSK bound avidly to GST-14-3-3beta but bound weakly to GST-14-3-3beta K49A (Fig. 1B). To demonstrate an in vivo interaction between RSK1 and 14-3-3beta in mammalian cells, HEK293 cells were transiently transfected with FLAG-RSK1 and Xpress-14-3-3beta . Xpress-14-3-3beta immunoprecipitates were prepared, and their ability to interact with RSK1 was examined by Western blot. As shown in Fig. 1C (middle panels), 14-3-3beta interacted with RSK1 in vivo. The reverse immunoprecipitation (Fig. 1C, right panels) demonstrates that FLAG-RSK1 can also coprecipitate 14-3-3beta .

The Interaction between RSK and 14-3-3beta Requires Phosphorylation-- Many interactions with 14-3-3 are dependent on binding partner phosphorylation. To determine whether this is also the case for the RSK1-14-3-3beta interaction, PS127 cell lysates were incubated with alkaline phosphatase for 1 h at 37 °C before GST-14-3-3beta pull-down. As shown in Fig. 2A, phosphatase treatment (CIAP) inhibited the binding of RSK to 14-3-3beta in the absence but not the presence of phosphatase inhibitors. Hence dephosphorylation of RSK1 abolished its ability to bind 14-3-3beta . In support of this conclusion, treatment of intact cells with the broad spectrum serine/threonine protein kinase inhibitor staurosporine also decreased the binding of RSK1 to GST-14-3-3beta in vitro (Fig. 2B).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   Phosphorylation of RSK1 is required for the binding of 14-3-3beta . A, PS127 cell lysates were incubated with or without CIAP and then pulled down with GST-14-3-3beta beads. Lanes 1 and 4, control; lanes 2 and 5, 200 units of CIAP; lanes 3 and 6, 200 units of CIAP plus phosphatase inhibitors (Inh.). Proteins bound to beads were subjected to SDS-PAGE and immunoblotted with anti-RSK1 antibody. B, HEK293 cells transfected with FLAG-RSK1 were treated with 1 µM staurosporine (Stauro) for 1 h before lysis and pull-down with GST-14-3-3beta . Proteins bound to beads were subjected to SDS-PAGE and immunoblotted with anti-FLAG antibody.

Binding to 14-3-3 proteins is usually mediated via a RSXpSXP or RXXXpSXP consensus motif (12, 13). RSK1 contains a number of putative 14-3-3beta binding sites as shown in Fig. 3A (RLS154KEV, RLGS307GP, RDS363PGI, RGFS380FV, RDPS457EE, REAS513FV, RIS630S631GK, and RKLPS732TT). RSK1 constructs with indicated serine to alanine point mutations were transiently transfected into HEK293 cells, and the possible involvement of these motifs in the RSK1-14-3-3beta interaction was investigated using GST-14-3-3beta pull-down and coimmunoprecipitation assays. Pull-down experiments demonstrated that mutation of S154A within the motif RLS(154)KEV strongly reduced RSK1-14-3-3beta interaction, whereas the other mutations had little or no effect (Fig. 3B). Coimmunoprecipitation confirmed that RSK1S154A no longer bound to 14-3-3beta in vivo (Fig. 3C). These data suggest that RSK1 interacts with 14-3-3beta through phosphorylated serine 154. 


View larger version (63K):
[in this window]
[in a new window]
 
Fig. 3.   Association of RSK1 mutants with 14-3-3beta . A, sequence of rat RSK1 showing potential 14-3-3beta -binding motifs underlined. B, HEK293 cell lysates transfected with RSK1 containing serine to alanine mutants of potential 14-3-3beta -binding motifs were pulled down with GST-14-3-3beta beads. Proteins bound to beads were subjected to SDS-PAGE and immunoblotted with anti-RSK1 antibody. C, HEK293 cells were transfected with Xpress-14-3-3beta , and FLAG-RSK1 or FLAG-RSK1S154A. Cells transfected with empty vector were used as a control. The cell lysates were immunoprecipitated (IP) with anti-Xpress antibody and immunoblotted for FLAG-RSK1 (upper panel) or Xpress-14-3-3beta (middle panel). The lower panel shows equal expression of the RSK constructs.

Serum Stimulation Reduces the RSK1-14-3-3beta Interaction-- Because serum stimulates RSK1 activity, which then activates NHE1 through phosphorylation of serine 703 (increasing the NHE1-14-3-3 interaction) (4, 17), we investigated the effect of serum on the RSK1-14-3-3beta interaction. PS127 fibroblasts were stimulated with 20% serum, and RSK association with GST-14-3-3beta was determined in a pull-down assay. Binding of RSK1 to 14-3-3beta was decreased by 34.6 ± 7.5% in cells stimulated for 5 min, 36.2 ± 4.1% at 10 min, and 28.2 ± 6.5% at 20 min (p < 0.05; Fig. 4, A and B). This effect was also observed in HEK293 cells and Cos7 cells overexpressing exogenous RSK1 (data not shown). Preincubating PS127 cells for 30 min with the MEK1 inhibitor PD98059 (30 µM), which prevents agonist-stimulated ERK1/2 and RSK activation, reversed this inhibition (Fig. 4, A and B). As a control, NHE1 interaction with GST-14-3-3beta was verified. Binding of GST-14-3-3beta to NHE1 was stimulated by serum, and this stimulation was significantly inhibited by PD98059 treatment (Fig. 4C, especially at 10 and 20 min).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Serum stimulation inhibits the interaction between RSK1 and 14-3-3beta . PS127 cells were stimulated with 20% FBS for 0, 5, 10, and 20 min with and without pretreatment for 1 h with 30 µM PD98059, and the cell lysates were pulled down with GST-14-3-3beta beads. A, proteins bound to beads were subjected to SDS-PAGE and immunoblotted with anti-RSK1 antibody. Relative binding of RSK1 to 14-3-3beta is shown as mean ± S.E. of five experiments (bottom panel). B, densitometric analysis of relative binding of RSK1 to 14-3-3 interaction after serum stimulation. The values are normalized to the 0 time point, which was set at 100%. The results are expressed as the means ± S.E. *, p < 0.05 compared with control (n = 5). C, proteins bound to GST-14-3-3beta beads were subjected to SDS-PAGE and immunoblotted with anti-NHE1 antibody.

Subcellular Colocalization of RSK1 and 14-3-3-- 14-3-3 proteins function as scaffolding proteins and have been shown to affect the subcellular localization of interacting proteins (reviewed in Refs. 7 and 14). For example, 14-3-3 can sequester proteins in the cytosol and/or target them to the plasma membrane. RSK1 has previously been shown to be located in the cytosol under basal conditions and to translocate to the plasma membrane after stimulation where it becomes fully activated (3). Therefore, we determined the subcellular distribution of 14-3-3beta and RSK1 before and after serum stimulation using subcellular fractionation in PS127 fibroblasts. In the absence of serum, RSK1 and 14-3-3beta were predominantly localized in the cytosol. After stimulation with 20% fetal calf serum for 5 min, there was a significant translocation of both 14-3-3beta and RSK1 to the membrane fraction (Fig. 5A) In contrast, the distribution of actin was unchanged after fetal calf serum treatment (Fig. 5A). This translocation also occurred with endogenous RSK and 14-3-3beta in NIH3T3 cells and in HEK293 cells expressing exogenous RSK (data not shown).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 5.   After serum stimulation RSK1 and 14-3-3beta translocate to the membrane fraction. Postnuclear supernatants of PS127 cells were separated into cytosol and membrane fractions. Total, cytosol, and membrane fractions were subjected to SDS-PAGE and immunoblotted as shown. Note that four times more of the membrane fraction (v/v) was loaded as compared with cytosol and total fraction.

To demonstrate colocalization of RSK1 and 14-3-3beta in intact cells, Cos7 cells were transfected with FLAG-RSK1, and RSK1 and 14-3-3beta were visualized by immunofluoresence staining with anti-FLAG antibody and anti-14-3-3beta , antibody respectively (Fig. 6). In unstimulated Cos7 cells, RSK1 and 14-3-3beta appeared diffusely distributed in the cytoplasm with significant colocalization (Fig. 6A). In cells stimulated with 20% fetal calf serum for 5 min, both 14-3-3beta and RSK1 translocated to the periphery of the cells (Fig. 6B). Overlaying the two images demonstrated significant colocalization, which was greatest at the plasma membrane (Fig. 6B).


View larger version (100K):
[in this window]
[in a new window]
 
Fig. 6.   Subcellular colocalization of 14-3-3beta and RSK1. Cos7 cells plated on glass coverslips were transfected with FLAG-RSK1. After 36 h, the cells were either left untreated (Control) or stimulated with 20% FBS for 5 min. The cells were then fixed, permeabilized, and stained with anti-14-3-3beta antibody (red) or anti-FLAG antibody for RSK1 (green). A, control Cos7 cells stained for 14-3-3beta (left panel) or FLAG-RSK1 (middle panel) and overlaying of the two images (right panel). B, serum-stimulated Cos7 cells stained for 14-3-3beta (left panel) or FLAG-RSK1 (middle panel) and overlaying of the two images (right panel). The cells were visualized with a Olympus IX70 Fluoview confocal microscope. Bar, 10 µm.

14-3-3beta Inhibits the Kinase Activity of RSK1-- It is possible that RSK1 binding to 14-3-3 could either increase or decrease kinase activity based on previous reports (reviewed in Ref. 14). Because overexpressing a dominant negative 14-3-3 construct in cells would inhibit the Raf-MEK1-ERK pathway (20) and therefore decrease RSK kinase activity, it was not satisfactory to perform this experiment. Therefore, we determined the effect of incubating active recombinant RSK1 with 14-3-3beta in vitro. Recombinant RSK1 was preincubated with GST alone, GST-14-3-3beta K49Q, or GST-14-3-3beta for 4 h, and then a kinase assay was performed using S6 peptide as the substrate. The activity of RSK1 in the presence of GST-14-3-3beta was significantly reduced by ~50% as compared with GST alone or GST-14-3-3beta K49Q (Fig. 7A). This finding suggests that binding of RSK1 to 14-3-3 may suppress RSK1 activity in vivo.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 7.   14-3-3beta inhibits RSK1 kinase activity through interaction at S154. A, recombinant RSK1 was incubated overnight with 10 µg of GST alone, GST-14-3-3beta K49Q, or GST-14-3-3beta at 4 °C. Kinase activity was determined using S6 peptide as the substrate. The data are expressed as relative radioactivity (cpm) incorporated into S6 peptide. The results are the means ± S.E. *, p < 0.05. B, HEK293 cells were transfected with the activator plasmid for CREB (pFA2-CREB), the reporter gene for luciferase (pFR-Luc), and Renilla plasmid (pRL-TK). The cells were also transfected with either RSK1 wild type or RSK1 S154A mutant. After 24 h of serum starvation, the cells were stimulated with 20% serum for 6 h. CREB activity was measured by assaying for firefly luciferase values. Renilla luciferase activity was measured as an internal control, and the results are presented as relative luciferase activity. The results are the means ± S.E. *, p < 0.05 (n = 4). C, CREB activity was assayed as described in B at increasing doses of EGF. The results are the means ± S.E. (n = 3-6).

To assess the functional significance of the RSK-14-3-3 binding in vivo, we compared the kinase activity of wild type RSK1 to the non-14-3-3beta -binding RSK1S154A mutant using a luciferase reporter assay system to measure the activity of CREB. CREB is activated by cAMP-dependent protein kinase and by all three members of the RSK family (RSK1-3) in cells stimulated by activators of the Ras/MEK/ERK1/2 cascade (21-23). As shown in Fig. 7B, CREB activity in cells expressing RSK1 wild type (RSK1WT) was increased after serum stimulation. However, in cells overexpressing RSKS154A, there was an 80% increase in CREB basal activity and a 114% increase in serum-stimulated activity relative to RSK1WT. This suggests that 14-3-3 binding to RSKS154 inhibits RSK activity both basally and after activation with serum. We next investigated the effect of the RSK1S154A mutation on EGF-stimulated CREB activity. The cells were transfected with RSK1WT or RSK1S154A and stimulated for 6 h with different concentrations of EGF, after which CREB activity was measured. In cells transfected with RSK1S154A, the EGF dose-response curve was significantly shifted to the left compared with cells expressing RSK1WT (EC50 of 1 ng/ml versus 6 ng/ml; Fig. 7C), demonstrating that 14-3-3beta binding inhibits EGF-stimulated RSK1 activity and thus CREB activation.

The increased CREB activity in cells transfected with RSK1S154A versus those transfected with RSK1WT combined with the finding that 14-3-3beta and RSK1 interact maximally under basal conditions suggest that 14-3-3beta inhibits RSK1 by preventing its activation rather than by interfering with RSK1-substrate interaction. To verify this hypothesis we used phospho-specific antibodies targeting two phosphorylation sites on RSK1, Ser380 and Ser363. Ser380 is autophosphorylated basally, and it is further phosphorylated by the carboxyl-terminal RSK1 kinase domain upon docking and activation by ERK (1, 2, 24, 25). Ser363 phosphorylation is thought to occur subsequently, after translocation of the RSK-ERK complex to the plasma membrane (3). We found that in RSK1S154A constructs, phosphorylation of both Ser380 and Ser363 was increased basally (by 27.3 ± 2.6% and 137.9 ± 10.6% respectively, n = 3) and after 5 min of serum stimulation (by 35.9 ± 3.9 and 28.1 ± 2.8%, respectively, n = 3; Fig. 8, A and B), compared with RSK1WT. These data demonstrate that 14-3-3 inhibits the activation of RSK1.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 8.   14-3-3beta inhibits RSK1 kinase activity through inhibition of RSK1 phosphorylation. HEK293 cells were transfected with FLAG-RSK1 or FLAG-RSK1S154A. Cells transfected with empty vector were used as a control. The cells were treated with or without serum for 5 min and RSK1 constructs were immunoprecipitated (IP) with anti-FLAG antibody. A, immunoprecipitates were immunoblotted with p380 RSK antibody. The lower panel shows equal expression of the RSK constructs. B, immunoprecipitates were immunoblotted with p363 RSK antibody. The lower panel shows equal expression of the RSK constructs. The blots are representative of three similar experiments.

Because full activation of RSK requires plasma membrane translocation (3), the increased activity of RSK1S154A suggested an increase in the amount of this mutant at the plasma membrane compared with RSK1WT. Therefore, we performed subcellular fractionation in HEK293 cells overexpressing RSK1WT or RSK1S154A. The amount of RSK1S154A in the membrane fraction under basal conditions was increased by 28.3 ± 2.9% (p < 0.05) as compared with RSK1WT, whereas upon serum stimulation the relative amounts of RSK1WT and mutant in the membrane fraction were similar (Fig. 9, A and B).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 9.   The amount of RSK1S154A in the membrane fraction is increased under basal conditions as compared with RSK1WT. A, postnuclear supernatants of HEK293 cells transfected with RSK1WT or RSK1S154A were separated into cytosol and membrane fractions. The total and membrane fractions were subjected to SDS-PAGE and immunoblotted as shown. B, densitometric analysis of relative amounts of RSK1 and RSK1S154A in the membrane and total fractions basally (Control) and after serum stimulation. The values are relative to RSK1WT at each condition, which was set at 100%. The results are expressed as the means ± S.E. *, p < 0.05 (n = 5).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The major finding of the present study is that the serine/threonine kinase RSK1 is a 14-3-3-interacting protein whose activity is negatively regulated by 14-3-3. The association between RSK and 14-3-3beta was demonstrated by (i) the ability of a GST-14-3-3beta fusion protein to bind RSK1 from cell lysates, (ii) direct binding of in vitro translated RSK1 to GST-14-3-3beta , and (iii) coprecipitation of transfected 14-3-3beta and RSK1. An important role for phosphorylated serine was previously demonstrated using 14-3-3zeta mutated at lysine 49, which reduces the phosphoserine-mediated interaction of binding partners Bcr, Raf, Cbl, and Bad but not the phosphorylation-independent interaction with Bax (18, 19, 26). Mutation of lysine 49 (K49Q) in 14-3-3beta also abolished phosphoserine-dependent interaction with NHE1 (17). Association of 14-3-3beta and RSK1 was dependent on a phosphoserine type interaction based on three findings. First, 14-3-3beta K49Q exhibited greatly reduced binding to RSK. Second, binding was inhibited by alkaline phosphatase treatment in vitro. Third, the serine/threonine kinase inhibitor staurosporine decreased the RSK1-14-3-3 interaction in vivo.

14-3-3 proteins have previously been shown to bind mainly through the motifs RSXpSXP and RXXXpSXP, where pS denotes phosphoserine and X is any amino acid; however, there are strong preferences for particular amino acids over others in the X positions (12, 13). To locate binding sites in RSK1 we made eight serine to alanine mutations at close matches to these consensus motifs (RLS154KEV, RLGS307GP, RDS363PGI, RGFS380FV, RDPS457EE, REAS513FV, RIS630S631GK, and RKLPS732TT). Only mutation of serine 154 greatly diminished binding of RSK1 to 14-3-3beta both in vitro and in vivo, suggesting that phosphorylated serine 154 is the site of 14-3-3beta interaction with RSK1. Interestingly, this motif lies within a predicted coiled-coil domain of RSK (amino acids 151-173; analyzed using Lupas's method at the EMBnet-CH website). Coiled-coil domains are known to mediate protein-protein interactions (27) and have previously been shown to be involved in the interaction of gamma -aminobutyric acid, type B receptors with 14-3-3 proteins (28).

The activation of RSK is dependent on a combination of both phosphorylation and plasma membrane localization events. ERK phosphorylates RSK1 within the carboxyl-terminal domain, and the phosphoinositide dependent kinase PDK1 phosphorylates RSK1 within the NH2-terminal domain (1, 2). Richards et al. (3) demonstrated recently that stimulated RSK1 transiently associates with the plasma membrane before accumulating in the nucleus. They also showed that the activity of a kinase inactive RSK1 mutant lacking the ERK docking site could be restored by addition of a membrane-targeting myristoylation site to the level of myristoylated wild type RSK1. This suggests that ERK has a role in escorting RSK to a plasma membrane-associated complex, although the exact mechanism of localization of RSK remains unclear (3).

14-3-3 proteins have been shown to play an important role in the subcellular distribution of a variety of signaling proteins. They appear to have the ability to both sequester proteins in the cytosol (for example protein kinase Ctheta ; (29), dictoystelium myosin II heavy chain protein kinase C (30), and Raf1 (16, 31)) and to cause translocation to the plasma membrane (for example testicular protein kinase 1) (32). Data in the present study suggest that 14-3-3beta may play a role in sequestering RSK1 in the cytosol under basal conditions. RSK1-14-3-3beta binding is maximal when cells are quiescent, and significant colocalization can be seen using immunofluoresence.

Upon activation by serum, a portion of both RSK1 and 14-3-3beta translocate to the membrane fraction, and they partially colocalize in vivo at the plasma membrane. Serum also reduces 14-3-3beta binding to RSK1 by 30-40%. These results suggest that 14-3-3beta translocates with RSK1 to the plasma membrane, and once there the two proteins dissociate. This dissociation may be regulated in two ways. First, phosphatases are likely to play a role in dephosphorylating the RSK1-binding site (serine 154), and second, other 14-3-3beta binding partners located at the plasma membrane may compete for 14-3-3beta interaction. It is interesting to note that the Na+/H+ exchanger NHE1 has previously been shown to be a RSK substrate and that upon mitogen stimulation, 14-3-3beta binds at the site of RSK phosphorylation (4, 17). Therefore, once phosphorylated by RSK, NHE1 may be a competing binding protein for 14-3-3beta at the membrane.

In this study, incubation of RSK1 with GST-14-3-3beta inhibited RSK activity by 50%. It has been demonstrated that multiple other signaling proteins bind to 14-3-3 and that their activities are inhibited by 14-3-3. For example, 14-3-3 inhibits the activity of phosphatidylinositol 3-kinase (33), protein kinase C isoforms theta  (29) and µ (34), dictoystelium myosin II heavy chain protein kinase C (30), and testicular protein kinase 1 (32). We have identified Ser154 as a major 14-3-3-binding site and found that RSK1-14-3-3 interaction is reduced in S154A mutants. Using the activity of CREB, a transcription factor downstream of Raf (1, 22) as a functional readout for RSK activity, we further demonstrated that the S154A mutation increased basal and serum-stimulated RSK activity. In addition when a dose-response curve for EGF-dependent CREB stimulation was performed, the EC50 for RSK1S154A was significantly lower than that of wild type RSK1. Increased phosphorylation of two sites essential for RSK1 kinase activity (Ser380 and Ser363) in the RSK1S154A mutant as compared with RSK1WT both basally and after mitogen stimulation suggests a role for 14-3-3beta in the inhibition of RSK1 kinase activity by interfering with its phosphorylation.

These results suggest that 14-3-3 plays a role in maintaining RSK1 signaling fidelity. Under basal conditions it may prevent activation by weak ERK signals. It is possible that RSK1 is held in the cytoplasm in an inactive conformation by 14-3-3beta , thus blocking phosphorylation of RSK1 activation sites. Because activation of RSK requires plasma membrane localization, increased basal activity of the S154A mutant correlates well with increased amounts in the plasma membrane compared with RSK1WT. Therefore, 14-3-3 is not a major determinant of membrane translocation of RSK1, although immunofluorescence and membrane fractionation data suggest that the two proteins move in a complex to the plasma membrane before dissociating. Rather, 14-3-3 is a modulator of RSK1 kinase activity. At the plasma membrane, 14-3-3 may continue to alter the kinetics of RSK1 activity until complete dissociation of the proteins. Binding to14-3-3beta appears to mask phosphorylation sites in RSK1 crucial for its activation, and it may also block the access of substrates or ATP to the catalytic site of RSK1 or continue to maintain RSK1 in a partially inactive conformation. In this way, 14-3-3beta could play an important role in the negative feedback regulation of active RSK1. Our data suggest some similarities between the regulation of RSK1 and Raf by 14-3-3. There are two serine sites on Raf that bind to 14-3-3, serine 259 and serine 621 (12, 16, 35). The activity of the Raf S259A mutant is increased basally and after EGF stimulation to a greater extent than wild type Raf (16, 35-37), and the mutant has increased amounts in the plasma membrane, suggesting 14-3-3 binding to Ser259 antagonizes Raf activity by sequestering it in the cytosol (38, 39).

In summary, we demonstrate for the first time that RSK1 is a 14-3-3-binding protein and suggest a functional role of the 14-3-3beta /RSK1 interaction in vivo. Based on the model shown in Fig. 10, we propose that RSK1 and 14-3-3beta are bound in the cytosol, maintaining RSK1 in an inactive conformation. Upon stimulation with mitogens, both 14-3-3beta and RSK1 translocate to the plasma membrane. RSK1-14-3-3beta complexes dissociate at the plasma membrane, allowing full activation of RSK1. Finally, RSK1 phosphorylates substrates such as Ser703 of NHE1. This study demonstrates added complexity of the cellular regulation of RSK. Further understanding of the mechanisms of 14-3-3 regulation of RSK signaling will give insights into the role of RSK in cell growth and proliferation. Because previous studies by our laboratory have demonstrated increased RSK activity in cells and tissues of hypertensive animals, it will be of interest to study the potential role of 14-3-3 in this altered RSK regulation.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 10.   Model for the role of 14-3-3beta in regulation of RSK1 function. In unstimulated cells, RSK1 and 14-3-3beta bind in cytosol, perhaps maintaining RSK1 in an inactive conformation. On stimulation with mitogens, both 14-3-3beta and RSK1 translocate to the plasma membrane. RSK 14-3-3beta complexes then dissociate, allowing full activation of RSK1. RSK1 then phosphorylates plasma membrane substrates such as Ser703 of NHE1 and translocates to the nucleus to phosphorylate nuclear substrates.


    FOOTNOTES

* This work was supported by Grants RO1 HL44721 and HL07949 from the National Institutes of Health (to B. C. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Recipient of a fellowship from the Canadian Institutes of Health Research. Present address: INSERM U541, Paris, France.

§ To whom correspondence should be addressed: University of Rochester, Center for Cardiovascular Research, 601 Elmwood Ave., Rochester, NY 14642. Tel.: 585-273-1946; Fax: 585-273-1497; E-mail: Bradford_Berk@urmc.rochester.edu.

Published, JBC Papers in Press, March 4, 2003, DOI 10.1074/jbc.M208475200

    ABBREVIATIONS

The abbreviations used are: RSK, p90 ribosomal S6 kinase; CREB, cAMP response element-binding protein; CIAP, calf intestinal alkaline phosphatase, ERK, extracellular signal-related kinase; GST, glutathione S-transferase; MEK, mitogen-activated protein kinase/ERK kinase; NHE1, Na+/H+ exchanger isoform 1; PDK1, phosphoinositide-dependent protein kinase 1; EGF, epidermal growth factor; FBS, fetal bovine serum; RSK1WT, RSK1 wild type.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Frodin, M., and Gammeltoft, S. (1999) Mol. Cell. Endocrinol. 151, 65-77[CrossRef][Medline] [Order article via Infotrieve]
2. Richards, S. A., Fu, J., Romanelli, A., Shimamura, A., and Blenis, J. (1999) Curr. Biol. 9, 810-820[CrossRef][Medline] [Order article via Infotrieve]
3. Richards, S. A., Dreisbach, V. C., Murphy, L. O., and Blenis, J. (2001) Mol. Cell. Biol. 21, 7470-7480[Abstract/Free Full Text]
4. Takahashi, E., Abe, J., Gallis, B., Aebersold, R., Spring, D. J., Krebs, E. G., and Berk, B. C. (1999) J. Biol. Chem. 274, 20206-20214[Abstract/Free Full Text]
5. Fu, H., Subramanian, R. R., and Masters, S. C. (2000) Annu. Rev. Pharmacol. Toxicol. 40, 617-647[CrossRef][Medline] [Order article via Infotrieve]
6. Tzivion, G., Shen, Y. H., and Zhu, J. (2001) Oncogene 20, 6331-6338[CrossRef][Medline] [Order article via Infotrieve]
7. Muslin, A. J., and Xing, H. (2000) Cell Signal. 12, 703-709[CrossRef][Medline] [Order article via Infotrieve]
8. Yaffe, M. B. (2002) FEBS Lett. 513, 53-57[CrossRef][Medline] [Order article via Infotrieve]
9. Han, D. C., Rodriguez, L. G., and Guan, J. L. (2001) Oncogene 20, 346-357[CrossRef][Medline] [Order article via Infotrieve]
10. Masters, S. C., Pederson, K. J., Zhang, L., Barbieri, J. T., and Fu, H. (1999) Biochemistry 38, 5216-5221[CrossRef][Medline] [Order article via Infotrieve]
11. Wang, B., Yang, H., Liu, Y. C., Jelinek, T., Zhang, L., Ruoslahti, E., and Fu, H. (1999) Biochemistry 38, 12499-12504[CrossRef][Medline] [Order article via Infotrieve]
12. Muslin, A. J., Tanner, J. W., Allen, P. M., and Shaw, A. S. (1996) Cell 84, 889-897[Medline] [Order article via Infotrieve]
13. Yaffe, M. B., Rittinger, K., Volinia, S., Caron, P. R., Aitken, A., Leffers, H., Gamblin, S. J., Smerdon, S. J., and Cantley, L. C. (1997) Cell 91, 961-971[Medline] [Order article via Infotrieve]
14. van Hemert, M. J., Steensma, H. Y., and van Heusden, G. P. (2001) Bioessays 23, 936-946[CrossRef][Medline] [Order article via Infotrieve]
15. Fanger, G. R., Widmann, C., Porter, A. C., Sather, S., Johnson, G. L., and Vaillancourt, R. R. (1998) J. Biol. Chem. 273, 3476-3483[Abstract/Free Full Text]
16. Tzivion, G., Luo, Z., and Avruch, J. (1998) Nature 394, 88-92[CrossRef][Medline] [Order article via Infotrieve]
17. Lehoux, S., Abe, J., Florian, J. A., and Berk, B. C. (2001) J. Biol. Chem. 276, 15794-15800[Abstract/Free Full Text]
18. Wang, H., Zhang, L., Liddington, R., and Fu, H. (1998) J. Biol. Chem. 273, 16297-16304[Abstract/Free Full Text]
19. Zhang, L., Wang, H., Liu, D., Liddington, R., and Fu, H. (1997) J. Biol. Chem. 272, 13717-13724[Abstract/Free Full Text]
20. Xing, H., Zhang, S., Weinheimer, C., Kovacs, A., and Muslin, A. J. (2000) EMBO J. 19, 349-358[Abstract/Free Full Text]
21. Shaywitz, A. J., and Greenberg, M. E. (1999) Annu. Rev. Biochem. 68, 821-861[CrossRef][Medline] [Order article via Infotrieve]
22. Xing, J., Ginty, D. D., and Greenberg, M. E. (1996) Science 273, 959-963[Abstract]
23. Xing, J., Kornhauser, J. M., Xia, Z., Thiele, E. A., and Greenberg, M. E. (1998) Mol. Cell. Biol. 18, 1946-1955[Abstract/Free Full Text]
24. Frodin, M., Jensen, C. J., Merienne, K., and Gammeltoft, S. (2000) EMBO J. 19, 2924-2934[Abstract/Free Full Text]
25. Vik, T. A., and Ryder, J. W. (1997) Biochem. Biophys. Res. Commun. 235, 398-402[CrossRef][Medline] [Order article via Infotrieve]
26. Nomura, M., Shimizu, S., Sugiyama, T., Narita, M., Ito, T., Matsuda, H., and Tsujimoto, Y. (2002) J. Biol. Chem. 7, 7
27. Lupas, A. (1996) Trends Biochem. Sci 21, 375-382[CrossRef][Medline] [Order article via Infotrieve]
28. Couve, A., Kittler, J. T., Uren, J. M., Calver, A. R., Pangalos, M. N., Walsh, F. S., and Moss, S. J. (2001) Mol. Cell. Neurosci. 17, 317-328[CrossRef][Medline] [Order article via Infotrieve]
29. Meller, N., Liu, Y. C., Collins, T. L., Bonnefoy-Berard, N., Baier, G., Isakov, N., and Altman, A. (1996) Mol. Cell. Biol. 16, 5782-5791[Abstract]
30. Matto-Yelin, M., Aitken, A., and Ravid, S. (1997) Mol. Biol. Cell 8, 1889-1899[Abstract/Free Full Text]
31. Roy, S., McPherson, R. A., Apolloni, A., Yan, J., Lane, A., Clyde-Smith, J., and Hancock, J. F. (1998) Mol. Cell. Biol. 18, 3947-3955[Abstract/Free Full Text]
32. Toshima, J. Y., Toshima, J., Watanabe, T., and Mizuno, K. (2001) J. Biol. Chem. 276, 43471-43481[Abstract/Free Full Text]
33. Bonnefoy-Berard, N., Liu, Y. C., von Willebrand, M., Sung, A., Elly, C., Mustelin, T., Yoshida, H., Ishizaka, K., and Altman, A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10142-10146[Abstract]
34. Hausser, A., Storz, P., Link, G., Stoll, H., Liu, Y. C., Altman, A., Pfizenmaier, K., and Johannes, F. J. (1999) J. Biol. Chem. 274, 9258-9264[Abstract/Free Full Text]
35. Michaud, N. R., Fabian, J. R., Mathes, K. D., and Morrison, D. K. (1995) Mol. Cell. Biol. 15, 3390-3397[Abstract]
36. Morrison, D. K., Heidecker, G., Rapp, U. R., and Copeland, T. D. (1993) J. Biol. Chem. 268, 17309-17316[Abstract/Free Full Text]
37. Rommel, C., Radziwill, G., Moelling, K., and Hafen, E. (1997) Mech. Dev. 64, 95-104[CrossRef][Medline] [Order article via Infotrieve]
38. Light, Y., Paterson, H., and Marais, R. (2002) Mol. Cell. Biol. 22, 4984-4996[Abstract/Free Full Text]
39. Dhillon, A. S., Meikle, S., Yazici, Z., Eulitz, M., and Kolch, W. (2002) EMBO J. 21, 64-71[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.